首页> 外文期刊>Journal of Pathology: Journal of the Pathological Society of Great Britain and Ireland >Targeted next-generation sequencing and non-coding RNA expression analysis of clear cell papillary renal cell carcinoma suggests distinct pathological mechanisms from other renal tumour subtypes
【24h】

Targeted next-generation sequencing and non-coding RNA expression analysis of clear cell papillary renal cell carcinoma suggests distinct pathological mechanisms from other renal tumour subtypes

机译:针对透明细胞乳头状肾细胞癌的靶向下一代测序和非编码RNA表达分析表明与其他肾肿瘤亚型不同的病理机制

获取原文
获取原文并翻译 | 示例
           

摘要

Clear cell tubulopapillary renal cell carcinoma (CCPRCC) is a recently described rare renal malignancy that displays characteristic gross, microscopic and immunohistochemical differences from other renal tumour types. However, CCPRCC remains a very poorly understood entity. We therefore sought to elucidate some of the molecular mechanisms involved in this neoplasm by carrying out targeted next-generation sequencing (NGS) to identify associated mutations, and in addition examined the expression of non-coding (nc) RNAs. We identified multiple somatic mutations in CCPRCC cases, including a recurrent [3/14 cases (21%)] non-synonymous T992I mutation in the MET proto-oncogene, a gene associated with epithelial-to-mesenchymal transition (EMT). Using a microarray approach, we found that the expression of mature (n = 1105) and pre-miRNAs (n = 1105), as well as snoRNA and scaRNAs (n = 2214), in CCPRCC cases differed from that of clear cell renal cell carcinoma (CCRCC) or papillary renal cell carcinoma (PRCC) tumours. Surprisingly, and unlike other renal tumour subtypes, we found that all five members of the miR-200 family were over-expressed in CCPRCC cases. As these miRNAs are intimately involved with EMT, we stained CCPRCC cases for E-cadherin, vimentin and β-catenin and found that the tumour cells of all cases were positive for all three markers, a combination rarely reported in other renal tumours that could have diagnostic implications. Taken together with the mutational analysis, these data suggest that EMT in CCPRCC tumour cells is incomplete or blocked, consistent with the indolent clinical course typical of this malignancy. In summary, as well as describing a novel pathological mechanism in renal carcinomas, this study adds to the mounting evidence that CCPRCC should be formally considered a distinct entity. Microarray data have been deposited in the GEO database [GEO accession number (GSE51554)].
机译:透明细胞肾小管乳头状肾细胞癌(CCPRCC)是最近描述的罕见肾恶性肿瘤,与其他类型的肾肿瘤相比,表现出特征性的肉眼,显微镜和免疫组织化学差异。但是,CCPRCC仍然是一个了解甚少的实体。因此,我们寻求通过进行靶向的下一代测序(NGS)来鉴定相关突变,从而阐明该肿瘤中涉及的一些分子机制,并另外检查了非编码(nc)RNA的表达。我们在CCPRCC病例中发现了多种体细胞突变,包括MET原癌基因(与上皮间质转化(EMT)相关的基因)中的复发性[3/14例(21%)]非同义T992I突变。使用微阵列方法,我们发现CCPRCC病例中成熟(n = 1105)和pre-miRNA(n = 1105)以及snoRNA和scaRNA(n = 2214)的表达与透明细胞肾细胞的表达不同癌(CCRCC)或乳头状肾细胞癌(PRCC)肿瘤。令人惊讶的是,与其他肾肿瘤亚型不同,我们发现miPR-200家族的所有五个成员在CCPRCC病例中均过表达。由于这些miRNA与EMT密切相关,因此我们对CCPRCC病例的E-钙黏着蛋白,波形蛋白和β-连环蛋白进行了染色,发现所有病例的肿瘤细胞对所有三种标记物均呈阳性,这种组合在其他肾脏肿瘤中很少报道诊断意义。结合突变分析,这些数据表明CCPRCC肿瘤细胞中的EMT不完全或受阻,与这种恶性肿瘤的典型临床过程一致。总而言之,除了描述肾癌的一种新型病理机制外,这项研究还为越来越多的证据表明CCPRCC应该被正式认为是一个独特的实体。芯片数据已保存在GEO数据库中[GEO登录号(GSE51554)]。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号